Marc Tessier-Lavigne - Dec 28, 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Dec 28, 2021
Transactions value $
-$2,805,197
Form type
4
Date filed
12/30/2021, 08:59 PM
Previous filing
Dec 10, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Gift $0 -300K -11.79% $0.00 2.24M Oct 4, 2021 Direct F1, F2
transaction DNLI Common Stock Gift $0 +100K $0.00 100K Oct 4, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F1, F3
transaction DNLI Common Stock Sale -$166K -3.73K -3.73% $44.37 96.3K Dec 28, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F3, F4
transaction DNLI Common Stock Sale -$470K -10.7K -11.11% $43.88 85.6K Dec 29, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F3, F5
transaction DNLI Common Stock Sale -$151K -3.34K -3.91% $45.13 82.2K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F3, F6
transaction DNLI Common Stock Sale -$154K -3.38K -4.11% $45.59 78.8K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F3, F7
transaction DNLI Common Stock Gift $0 +100K $0.00 100K Oct 4, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F1, F8
transaction DNLI Common Stock Sale -$160K -3.6K -3.6% $44.38 96.4K Dec 28, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F8, F9
transaction DNLI Common Stock Sale -$469K -10.7K -11.1% $43.87 85.7K Dec 29, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F8, F10
transaction DNLI Common Stock Sale -$255K -5.63K -6.56% $45.31 80.1K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F8, F11
transaction DNLI Common Stock Sale -$41.1K -900 -1.12% $45.71 79.2K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F8, F12
transaction DNLI Common Stock Gift $0 +100K $0.00 100K Oct 4, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F1, F13
transaction DNLI Common Stock Sale -$162K -3.65K -3.65% $44.37 96.4K Dec 28, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F13, F14
transaction DNLI Common Stock Sale -$470K -10.7K -11.11% $43.88 85.7K Dec 29, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F13, F15
transaction DNLI Common Stock Sale -$272K -6K -7.01% $45.31 79.6K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F13, F16
transaction DNLI Common Stock Sale -$36.6K -800 -1% $45.72 78.8K Dec 30, 2021 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F13, F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift.
F2 Includes 2,074 restricted stock units.
F3 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.42 to $45.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F7 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.42 to $45.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F8 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F9 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F10 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.51 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F11 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F12 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.66 to $45.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F13 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
F14 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.18 to $44.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F15 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F16 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F17 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.67 to $45.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.